Sangamo Therapeutics (SGMO)

$0.50 -0.03 (-6.45%)
Market Cap 166.87M
Revenue (ttm) 57.80M
Net Income (ttm) -97.94M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -169.45%
Debt to Equity Ratio 0.00
Volume 5,023,900
Avg Vol 6,818,092
Day's Range N/A - N/A
Shares Out 336.50M
Stochastic %K 63%
Beta 1.41
Analysts Sell
Price Target $3.25

Company Profile

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 970 6000
Address:
501 Canal Blvd, Richmond, United States
BobbyAxel
BobbyAxel Dec. 7 at 4:52 AM
$SGMO Tha VP job opening seems to be filled
0 · Reply
Swamp_Yankee
Swamp_Yankee Dec. 7 at 1:08 AM
$SGMO Sandy got a fake tree
0 · Reply
andre1153
andre1153 Dec. 6 at 8:28 PM
$SGMO the signs are all there!!!
0 · Reply
rneeed
rneeed Dec. 5 at 10:25 PM
$SGMO
0 · Reply
Kaysaaa81
Kaysaaa81 Dec. 5 at 10:00 PM
$SGMO A good week, however, no more kicking the can!!! Shareholders & patients deserve action: VC cash, a strategic sale, or a partnership beyond BP. $SGMO looks primed for a catalyst: Strong accumulation + runway pressure + sequential catalysts (ST-503 → deal) = setup for the next leg. Stage 1: ST-503 Fast Track Stage 2: Transaction With buy pressure rising and borrow tightening, the market is clearly expecting a catalyst. $SGMO should, actually must, announce before Christmas preferably next week, to reinforce management credibility & protect shareholder confidence.
3 · Reply
Plyaden
Plyaden Dec. 5 at 9:32 PM
$SGMO wtf are those 5 $ Calls 2027? 🫨
5 · Reply
pdwpdw
pdwpdw Dec. 5 at 8:03 PM
$SGMO Below is my near-in daily technical chart (Click on image to enlarge). Yesterday's price rise triggered a small inverse head and shoulder pattern projecting to 70 Cents (see grey neckline and projection line), and price today is retesting that neckline. More generally, price sits just below the 100, 50, and 200 day moving averages, suggesting some days of consolidation ahead absent news or rumor. Looking leftward on the chart, there are many triggered-and-still-valid inverse head and shoulder patterns targeting from 70 cents to $1.30.
2 · Reply
andre1153
andre1153 Dec. 5 at 5:13 PM
$SGMO that depends on your risk management. Should you drop every lad penny you have on this… only you can tell yourself if it is worth buying this
0 · Reply
andre1153
andre1153 Dec. 5 at 5:00 PM
$SGMO a little buying opportunity!! Won’t be this low for long!! I’m getting it while it’s fresh
0 · Reply
PaddyIce87
PaddyIce87 Dec. 5 at 4:55 PM
$SGMO Happened pretty quickly thereafter, maybe an hour or so, but really don’t want to retest .50 again. Turn this ship around ! Three days of green!
1 · Reply
Latest News on SGMO
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy

Dec 2, 2025, 8:05 AM EST - 5 days ago

Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy

Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease

Nov 21, 2025, 8:05 AM EST - 16 days ago

Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease

Sangamo Therapeutics, Inc. (SGMO) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 11:56 PM EST - 4 weeks ago

Sangamo Therapeutics, Inc. (SGMO) Q3 2025 Earnings Call Transcript

Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results

Nov 6, 2025, 8:01 AM EST - 4 weeks ago

Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results

Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call

Oct 30, 2025, 4:01 PM EDT - 5 weeks ago

Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025

Sep 4, 2025, 8:05 AM EDT - 3 months ago

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025

Sangamo Therapeutics, Inc. (SGMO) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 2:53 PM EDT - 4 months ago

Sangamo Therapeutics, Inc. (SGMO) Q2 2025 Earnings Call Transcript

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results

Aug 7, 2025, 4:01 PM EDT - 4 months ago

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results

Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call

Jul 31, 2025, 4:05 PM EDT - 4 months ago

Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease

Jun 24, 2025, 8:05 AM EDT - 5 months ago

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease

Sangamo Therapeutics, Inc. (SGMO) Q1 2025 Earnings Call Transcript

May 12, 2025, 9:06 PM EDT - 7 months ago

Sangamo Therapeutics, Inc. (SGMO) Q1 2025 Earnings Call Transcript

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results

May 12, 2025, 6:26 PM EDT - 7 months ago

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results

Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering

May 12, 2025, 6:23 PM EDT - 7 months ago

Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering

Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day

May 12, 2025, 4:00 PM EDT - 7 months ago

Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day

Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

May 6, 2025, 4:35 PM EDT - 7 months ago

Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease

May 6, 2025, 8:30 AM EDT - 7 months ago

Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease

Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Apr 28, 2025, 4:31 PM EDT - 7 months ago

Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal

Apr 4, 2025, 2:57 PM EDT - 8 months ago

Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System

Apr 3, 2025, 4:01 PM EDT - 8 months ago

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System

Sangamo Therapeutics, Inc. (SGMO) Q4 2024 Earnings Call Transcript

Mar 17, 2025, 6:29 PM EDT - 9 months ago

Sangamo Therapeutics, Inc. (SGMO) Q4 2024 Earnings Call Transcript

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Mar 17, 2025, 4:01 PM EDT - 9 months ago

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference

Mar 6, 2025, 4:05 PM EST - 9 months ago

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile

Feb 6, 2025, 8:05 AM EST - 10 months ago

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sangamo Therapeutics, Inc. (SGMO) And Encourages Shareholders to Reach Out

Jan 15, 2025, 10:00 AM EST - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sangamo Therapeutics, Inc. (SGMO) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Shareholders to Learn More About the Investigation

Jan 14, 2025, 10:00 AM EST - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Shareholders to Learn More About the Investigation

Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jan 13, 2025, 10:00 AM EST - 11 months ago

Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Shareholders to Inquire about Securities Investigation

Jan 12, 2025, 10:00 AM EST - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Shareholders to Inquire about Securities Investigation

Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jan 10, 2025, 10:00 AM EST - 11 months ago

Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sangamo Therapeutics, Inc. (SGMO) And Encourages Investors to Connect

Jan 9, 2025, 10:00 AM EST - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sangamo Therapeutics, Inc. (SGMO) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Stockholders to Inquire about Securities Investigation

Jan 8, 2025, 10:00 AM EST - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Investors to Learn More About the Investigation

Jan 7, 2025, 10:00 AM EST - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Investors to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sangamo Therapeutics, Inc. (SGMO) And Encourages Stockholders to Connect

Jan 6, 2025, 10:00 AM EST - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sangamo Therapeutics, Inc. (SGMO) And Encourages Stockholders to Connect

Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Jan 5, 2025, 10:00 AM EST - 1 year ago

Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Stockholders to Learn More About the Investigation

Jan 3, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Stockholders to Learn More About the Investigation

Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

Jan 2, 2025, 6:00 PM EST - 1 year ago

Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

BobbyAxel
BobbyAxel Dec. 7 at 4:52 AM
$SGMO Tha VP job opening seems to be filled
0 · Reply
Swamp_Yankee
Swamp_Yankee Dec. 7 at 1:08 AM
$SGMO Sandy got a fake tree
0 · Reply
andre1153
andre1153 Dec. 6 at 8:28 PM
$SGMO the signs are all there!!!
0 · Reply
rneeed
rneeed Dec. 5 at 10:25 PM
$SGMO
0 · Reply
Kaysaaa81
Kaysaaa81 Dec. 5 at 10:00 PM
$SGMO A good week, however, no more kicking the can!!! Shareholders & patients deserve action: VC cash, a strategic sale, or a partnership beyond BP. $SGMO looks primed for a catalyst: Strong accumulation + runway pressure + sequential catalysts (ST-503 → deal) = setup for the next leg. Stage 1: ST-503 Fast Track Stage 2: Transaction With buy pressure rising and borrow tightening, the market is clearly expecting a catalyst. $SGMO should, actually must, announce before Christmas preferably next week, to reinforce management credibility & protect shareholder confidence.
3 · Reply
Plyaden
Plyaden Dec. 5 at 9:32 PM
$SGMO wtf are those 5 $ Calls 2027? 🫨
5 · Reply
pdwpdw
pdwpdw Dec. 5 at 8:03 PM
$SGMO Below is my near-in daily technical chart (Click on image to enlarge). Yesterday's price rise triggered a small inverse head and shoulder pattern projecting to 70 Cents (see grey neckline and projection line), and price today is retesting that neckline. More generally, price sits just below the 100, 50, and 200 day moving averages, suggesting some days of consolidation ahead absent news or rumor. Looking leftward on the chart, there are many triggered-and-still-valid inverse head and shoulder patterns targeting from 70 cents to $1.30.
2 · Reply
andre1153
andre1153 Dec. 5 at 5:13 PM
$SGMO that depends on your risk management. Should you drop every lad penny you have on this… only you can tell yourself if it is worth buying this
0 · Reply
andre1153
andre1153 Dec. 5 at 5:00 PM
$SGMO a little buying opportunity!! Won’t be this low for long!! I’m getting it while it’s fresh
0 · Reply
PaddyIce87
PaddyIce87 Dec. 5 at 4:55 PM
$SGMO Happened pretty quickly thereafter, maybe an hour or so, but really don’t want to retest .50 again. Turn this ship around ! Three days of green!
1 · Reply
JanuszDoge
JanuszDoge Dec. 5 at 4:52 PM
$SGMO Is it worth buying shares?
0 · Reply
ttesttestt
ttesttestt Dec. 5 at 4:05 PM
$SGMO hate the mgmt, but potential is too big. Holding 15k for a short range
1 · Reply
CheesyBurrito
CheesyBurrito Dec. 5 at 2:46 PM
$SGMO Looks like some opening-bell tax-loss selling today. I suspect today will follow the same pattern as the last two days: early morning red, then consolidation with nibble-buying and a turn to green by midday, closing a penny or two higher than yesterday.
2 · Reply
JGHersh
JGHersh Dec. 5 at 2:38 PM
$SGMO another opportunity for me to buy shares. I love the people selling.
0 · Reply
BioAmerica
BioAmerica Dec. 5 at 2:12 PM
$SGMO $XBI
0 · Reply
biotech
biotech Dec. 5 at 2:10 PM
$SGMO $XBI FDA announces major #deregulatory push to speed up cures Commissioner Dr. Marty Makary joins #FOX 'Mornings with Maria' to unveil the push to slash red tape, #accelerate life-saving drug approvals https://foxbusiness.com/video/63860333
0 · Reply
Top_Dog_Pro_Trader
Top_Dog_Pro_Trader Dec. 5 at 1:52 PM
$SGMO FDA Director says they will prioritize drugs that reduce down stream costs: sounds like Fabry, HemA and SGMO’s pipeline as a whole to me! Ignore the swing traders and penny flippers scare mongering on short term crap. This will explode on any pipeline, partnership, voucher, etc, news!
0 · Reply
JGHersh
JGHersh Dec. 5 at 1:43 PM
$SGMO please ignore the noise. Carefully study the science and what the company is advancing. Tell me it’s only worth .53 and prove it. I say minimum $5-6. Do not sell tge shares. When good news hits the long term investors will be rewarded. Manipulation is an art. Stay focused. Remember this is not QURE.
1 · Reply
JimiJoJeeter
JimiJoJeeter Dec. 5 at 12:48 PM
$SGMO Major hurdles for the month are short interest publication for the back half of November on the 9th and OpEx Friday the 19th. Short interest reports again on the 24th but if no deals or great news by the 19th, this puppy is done for the year. My best guess would be, without more great news or some deal, we end the year between $0.36 and $0.66. Again, with nothing material, I find it hard to believe the Dec $0.5 or $1.0 calls will be even remotely in the money.... JMHO.
4 · Reply
Kaysaaa81
Kaysaaa81 Dec. 5 at 10:43 AM
$SGMO Dec 4th article……
0 · Reply
lpalmieri
lpalmieri Dec. 5 at 10:27 AM
$SGMO can we have a fatfinger trade at $52 rather than $0.52? lmao
1 · Reply
notnowson
notnowson Dec. 5 at 10:27 AM
$SGMO
0 · Reply